{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T16:38:00Z","timestamp":1740155880261,"version":"3.37.3"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1038\/s41584-022-00789-1","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T12:03:03Z","timestamp":1652443383000},"page":"481-489","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Improving the design of RCTs in non-radiographic axial spondyloarthritis"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-1755","authenticated-orcid":false,"given":"Walter P.","family":"Maksymowych","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert G. W.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liron","family":"Caplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip E.","family":"van den Bosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikkel","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"789_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9","volume":"43","author":"JJ Anderson","year":"2000","unstructured":"Anderson, J. J. et al. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum. 43, 22\u201329 (2000).","journal-title":"Arthritis Rheum."},{"key":"789_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.2312","volume":"5","author":"R Wang","year":"2022","unstructured":"Wang, R. et al. Predicting probability of response to tumor necrosis factor inhibitors for individual patients with ankylosing spondylitis. JAMA Netw. Open 5, e222312 (2022).","journal-title":"JAMA Netw. Open"},{"key":"789_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/annrheumdis-2012-201972","volume":"73","author":"E Theander","year":"2014","unstructured":"Theander, E. et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann. Rheum. Dis. 73, 407\u2013413 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"789_CR4","unstructured":"FDA. Rheumatoid Arthritis: Developing Drug Products for Treatment. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/rheumatoid-arthritis-developing-drug-products-treatment (2013)."},{"key":"789_CR5","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of rheumatoid arthritis. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-rheumatoid-arthritis_en.pdf (2018)."},{"key":"789_CR6","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of psoriatic arthritis. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-psoriatic-arthritis_en.pdf (2007)."},{"key":"789_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000057","volume":"1","author":"S Monti","year":"2015","unstructured":"Monti, S. et al. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open. 1, e000057 (2015).","journal-title":"RMD Open."},{"key":"789_CR8","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.berh.2012.10.003","volume":"26","author":"WP Maksymowych","year":"2012","unstructured":"Maksymowych, W. P. Controversies in conventional radiography in spondyloarthritis. Best. Pract. Res. Clin. Rheumatol. 26, 839\u2013852 (2012).","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"789_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3899\/jrheum.160079","volume":"44","author":"AA Christiansen","year":"2017","unstructured":"Christiansen, A. A. et al. Limited reliability of radiographic assessment of sacroiliac joints in patients with suspected early spondyloarthritis. J. Rheumatol. 44, 70\u201377 (2017).","journal-title":"J. Rheumatol."},{"key":"789_CR10","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1002\/art.38738","volume":"66","author":"R van den Berg","year":"2014","unstructured":"van den Berg, R. et al. Agreement between clinical practice and trained central reading in reading of sacroiliac joints on plain pelvic radiographs. Results from the DESIR cohort. Arthritis Rheumatol. 66, 2403\u20132411 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"789_CR11","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/art.20990","volume":"52","author":"M Rudwaleit","year":"2005","unstructured":"Rudwaleit, M. et al. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum. 52, 1000\u20131008 (2005).","journal-title":"Arthritis Rheum."},{"key":"789_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden, S. et al. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 27, 361\u2013368 (1984).","journal-title":"Arthritis Rheum."},{"key":"789_CR13","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/art.24483","volume":"60","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit, M. et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum. 60, 712\u2013727 (2009).","journal-title":"Arthritis Rheum."},{"key":"789_CR14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit, M. et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann. Rheum. Dis. 68, 777\u2013783 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"789_CR15","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1136\/ard.2009.110767","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit, M. et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS\/OMERACT MRI group. Ann. Rheum. Dis. 68, 1520\u20131527 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"789_CR16","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1136\/annrheumdis-2015-208642","volume":"75","author":"RGW Lambert","year":"2016","unstructured":"Lambert, R. G. W. et al. Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. Ann. Rheum. Dis. 75, 1958\u20131963 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"789_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3899\/jrheum.161232","volume":"44","author":"D Poddubnyy","year":"2017","unstructured":"Poddubnyy, D. Radiographic evaluation of sacroiliac joints in axial spondyloarthritis\u2013still worth performing? J. Rheumatol. 44, 1\u20133 (2017).","journal-title":"J. Rheumatol."},{"key":"789_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1136\/ard.62.6.519","volume":"62","author":"A van Tubergen","year":"2003","unstructured":"van Tubergen, A. et al. Radiographic assessment of sacroiliitis by radiologists and rheumatologists: does training improve quality? Ann. Rheum. Dis. 62, 519\u2013525 (2003).","journal-title":"Ann. Rheum. Dis."},{"key":"789_CR19","unstructured":"Bennett, P. H. & Burch, T. A. (eds) Population Studies of the Rheumatic Diseases. 456\u2013457 (Excerpta Medica Foundation, 1968)."},{"key":"789_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1055\/s-2008-1067939","volume":"12","author":"MJ Tuite","year":"2008","unstructured":"Tuite, M. J. Sacroiliac joint imaging. Semin. Musculoskelet. Radiol. 12, 72\u201382 (2008).","journal-title":"Semin. Musculoskelet. Radiol."},{"key":"789_CR21","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1136\/annrheumdis-2014-205432","volume":"74","author":"R van den Berg","year":"2015","unstructured":"van den Berg, R. et al. Classification of axial SpA based on positive imaging (radiographs and\/or MRI of the sacroiliac joints) by local rheumatologists or radiologists versus central trained readers in the DESIR cohort. Ann. Rheum. Dis. 74, 2016\u20132021 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"789_CR22","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/annrheumdis-2019-215589","volume":"78","author":"WP Maksymowych","year":"2019","unstructured":"Maksymowych, W. P. et al. MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. Ann. Rheum. Dis. 78, 1550\u20131558 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"789_CR23","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/art.38776","volume":"66","author":"A Deodhar","year":"2014","unstructured":"Deodhar, A. et al. The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration\u2019s comments and concerns. Arthritis Rheumatol. 66, 2649\u20132656 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"789_CR24","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","volume":"68","author":"J Sieper","year":"2009","unstructured":"Sieper, J. et al. The Assessment of Spondyloarthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann. Rheum. Dis. 68, ii1\u2013ii44 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"789_CR25","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1002\/art.23606","volume":"58","author":"H Haibel","year":"2008","unstructured":"Haibel, H. et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis. Arthritis Rheumatol. 58, 1981\u20131991 (2008).","journal-title":"Arthritis Rheumatol."},{"key":"789_CR26","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1136\/ard.2010.139667","volume":"70","author":"IH Song","year":"2011","unstructured":"Song, I. H. et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomized controlled trial. Ann. Rheum. Dis. 70, 590\u2013596 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"789_CR27","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/art.24408","volume":"60","author":"N Barkham","year":"2009","unstructured":"Barkham, N. et al. Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum. 60, 946\u2013954 (2009).","journal-title":"Arthritis Rheum."},{"key":"789_CR28","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper, J. et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann. Rheum. Dis. 72, 815\u2013822 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"789_CR29","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde, D. et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Arthritis Rheumatol. 54, 2136\u20132146 (2006).","journal-title":"Arthritis Rheumatol."},{"key":"789_CR30","first-page":"735","volume":"68","author":"J Sieper","year":"2016","unstructured":"Sieper, J. et al. Impact of time since diagnosis, age, and number of prior non-steroidal anti-in!ammatory drugs on response to adalimumab in patients with ankylosing spondylitis. Arthritis Rheumatol. 68, 735 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"789_CR31","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1136\/annrheumdis-2012-202389","volume":"72","author":"IH Song","year":"2013","unstructured":"Song, I. H. et al. Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. Ann. Rheum. Dis. 72, 823\u2013825 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"789_CR32","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1136\/annrheumdis-2015-207596","volume":"75","author":"WP Maksymowych","year":"2016","unstructured":"Maksymowych, W. P. et al. Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study. Ann. Rheum. Dis. 75, 1328\u20131335 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"789_CR33","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde, D. et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 52, 582\u2013591 (2005).","journal-title":"Arthritis Rheum."},{"key":"789_CR34","first-page":"2702","volume":"67","author":"J Sieper","year":"2015","unstructured":"Sieper, J. et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Ann. Rheum. Dis. 67, 2702\u20132712 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"789_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landew\u00e9","year":"2014","unstructured":"Landew\u00e9, R. et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann. Rheum. Dis. 73, 39\u201347 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"789_CR36","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/art.40866","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar, A. et al. A fifty-two-week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 71, 1101\u20131111 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"789_CR37","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman, R. D. et al. Efficacy and safety of Golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 58, 3402\u20133412 (2008).","journal-title":"Arthritis Rheum."},{"key":"789_CR38","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/art.41477","volume":"73","author":"A Deodhar","year":"2021","unstructured":"Deodhar, A. et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study. Arthritis Rheumatol. 73, 110\u2013120 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"789_CR39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar, A. et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet 395, 53\u201364 (2020).","journal-title":"Lancet"},{"key":"789_CR40","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten, D. et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N. Engl. J. Med. 373, 2534\u20132548 (2015).","journal-title":"N. Engl. J. Med."},{"key":"789_CR41","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde, D. et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet 392, 2441\u20132451 (2018).","journal-title":"Lancet"},{"key":"789_CR42","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13075-021-02650-4","volume":"23","author":"WP Maksymowych","year":"2021","unstructured":"Maksymowych, W. P. et al. Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol. Arthritis Res. Ther. 23, 274 (2021).","journal-title":"Arthritis Res. Ther."},{"key":"789_CR43","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13075-016-1093-z","volume":"18","author":"JJ de Winter","year":"2016","unstructured":"de Winter, J. J. et al. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a metaanalysis. Arthritis Res. Ther. 18, 196 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"789_CR44","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/acr.22180","volume":"66","author":"L van Hoeven","year":"2014","unstructured":"van Hoeven, L. et al. Identifying axial spondyloarthritis in Dutch primary care patients, ages 20\u201345 years, with chronic low back pain. Arthritis Care. Res. 66, 446\u2013453 (2014).","journal-title":"Arthritis Care. Res."},{"key":"789_CR45","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1136\/annrheumdis-2020-217769","volume":"79","author":"D Porter","year":"2020","unstructured":"Porter, D. et al. Classification criteria: time for a rethink? Ann. Rheum. Dis. 79, 1264\u20131266 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"789_CR46","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/art.40475","volume":"70","author":"J De Winter","year":"2018","unstructured":"De Winter, J. et al. Magnetic resonance imaging of the sacroiliac joints indicating sacroiliitis according to the Assessment of SpondyloArthritis International Society definition in healthy individuals, runners, and women with postpartum back pain. Arthritis Rheumatol. 70, 1042\u20131048 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"789_CR47","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/art.40429","volume":"70","author":"U Weber","year":"2018","unstructured":"Weber, U. et al. Frequency and anatomic distribution of magnetic resonance imaging features in the sacroiliac joints of young athletes: exploring \u201cbackground noise\u201d toward a data-driven definition of sacroiliitis in early spondyloarthritis. Arthritis Rheumatol. 70, 736\u2013745 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"789_CR48","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/rheumatology\/kex491","volume":"57","author":"G Varkas","year":"2018","unstructured":"Varkas, G. et al. Effect of mechanical stress on magnetic resonance imaging of the sacroiliac joints: assessment of military recruits by magnetic resonance imaging study. Rheumatology 57, 508\u2013513 (2018).","journal-title":"Rheumatology"},{"key":"789_CR49","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/art.38721","volume":"66","author":"M Dougados","year":"2016","unstructured":"Dougados, M. et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 66, 2091\u20132102 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"789_CR50","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1093\/rheumatology\/keab099","volume":"60","author":"WP Maksymowych","year":"2021","unstructured":"Maksymowych, W. P. et al. Data-driven definitions for active and structural MRI lesions in the sacroiliac joint in spondyloarthritis and their predictive utility. Rheumatology 60, 4778\u20134789 (2021).","journal-title":"Rheumatology"},{"key":"789_CR51","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1002\/art.41037","volume":"71","author":"S Seven","year":"2019","unstructured":"Seven, S. et al. Magnetic resonance imaging of lesions in the sacroiliac joints for differentiation of patients with axial spondyloarthritis from control subjects with or without pelvic or buttock pain: a prospective, cross-sectional study of 204 participants. Arthritis Rheumatol. 71, 2034\u20132046 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"789_CR52","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/acr.23244","volume":"70","author":"A Latourte","year":"2018","unstructured":"Latourte, A. et al. Imaging findings suggestive of axial spondyloarthritis in diffuse idiopathic skeletal hyperostosis. Arthritis Care Res. 70, 145\u2013152 (2018).","journal-title":"Arthritis Care Res."},{"key":"789_CR53","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1136\/annrheumdis-2015-207823","volume":"75","author":"M de Hooge","year":"2016","unstructured":"de Hooge, M. et al. Patients with chronic back pain of short duration from the SPACE cohort: which MRI structural lesions in the sacroiliac joints and inflammatory and structural lesions in the spine are most specific for axial spondyloarthritis? Ann. Rheum. Dis. 75, 1308\u20131314 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"789_CR54","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/art.21445","volume":"53","author":"WP Maksymowych","year":"2005","unstructured":"Maksymowych, W. P. et al. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum. 53, 703\u2013709 (2005).","journal-title":"Arthritis Rheum."},{"key":"789_CR55","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3899\/jrheum.140519","volume":"42","author":"WP Maksymowych","year":"2015","unstructured":"Maksymowych, W. P. et al. Development and preliminary validation of the spondyloarthritis research Consortium of Canada magnetic resonance imaging sacroiliac joint structural score. J. Rheumatol. 42, 79\u201386 (2015).","journal-title":"J. Rheumatol."},{"key":"789_CR56","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03993847 (2021)."},{"key":"789_CR57","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrrheum.2014.181","volume":"11","author":"A van Tubergen","year":"2015","unstructured":"van Tubergen, A. The changing clinical picture and epidemiology of spondyloarthritis. Nat. Rev. Rheumatol. 11, 110\u2013118 (2015).","journal-title":"Nat. Rev. Rheumatol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00789-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00789-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00789-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,13]],"date-time":"2022-11-13T14:06:04Z","timestamp":1668348364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00789-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["789"],"URL":"https:\/\/doi.org\/10.1038\/s41584-022-00789-1","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"type":"print","value":"1759-4790"},{"type":"electronic","value":"1759-4804"}],"subject":[],"published":{"date-parts":[[2022,5,13]]},"assertion":[{"value":"29 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.P.M. is Chief Medical Officer of CARE Arthritis Limited, has acted as a paid consultant\/participated in advisory boards for AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer and UCB; received research and\/or educational grants from AbbVie, Novartis, Pfizer and UCB; received speaker fees from AbbVie, Janssen, Novartis, Pfizer and UCB; and is a member of the ASAS-MRI Working Group. R.G.W.L. has consulted for AbbVie, CARE Arthritis, Parexel, Pfizer and UCB; and is a member of the ASAS-MRI Working Group. F.v.d.B. has received consultancy fees and\/or speaker fees from AbbVie, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer and UCB Pharma. M.\u00d8. has received grant\/research support from AbbVie, Bristol-Myers Squibb, Celgene, Merck and Novartis; has worked as a paid consultant for AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, CARE Arthritis, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Novo Nordisk, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB; and received speaker fees from AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Orion, Pfizer, Roche, Sandoz, Sanofi and UCB, and is a member of the ASAS-MRI Working Group. L.C. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}